BUZZ-Certara rises after Q1 preliminary results, share repurchase program

Reuters
14 Apr
BUZZ-Certara rises after Q1 preliminary results, share repurchase program 

** Shares of drug development software provider Certara CERT.O rise 7.8% to $13.91

** Co expects prelim Q1 revenue of $106 million, above analysts' average estimate of $104.4 million as per data compiled by LSEG

** CERT expects 2025 revenue in the range of $415 million to $425 million, analysts' on average expect 2025 revenue of $419.8 million

** Co says its board has authorized a $100 million share repurchase program

** Separately, co launches an AI-enabled clinical assistance software to aid drug development that will reduce, refine, or replace animal testing

** The move comes after the U.S. FDA said it plans to replace animal testing in the development of monoclonal antibody therapies and other drugs with "human-relevant methods," including the use of AI-based models

** Including session's move, CERT up 31.2% YTD

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10